SG11201809652PA - Treatment of skin lesions - Google Patents
Treatment of skin lesionsInfo
- Publication number
- SG11201809652PA SG11201809652PA SG11201809652PA SG11201809652PA SG11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formula
- independently
- optionally substituted
- basel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 Oil Mil 11111001101111111110 lil Oil lil Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/198347 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: trasse 49b, 8102 Oberengstringen (CH). STUETZ, Anton; A61K 31/00 (2006.01) A61K 31/5386 (2006.01) Teichweg 4, 4813 Altmiinster (CH). SEYKORA, John, T.; A61K 31/5377 (2006.01) A61P 17/02 (2006.01) 202 Laurel Lane, Broomall, PA 19008 (US). BEAUFILS, (21) International Application Number: Florent; 28 rue des ecureuils, 68870 Bartenheim (FR). PCT/EP2017/025137 (74) Agent: SPERRLE, Martin; Austrasse 24, 4051 Basel (22) International Filing Date: (CH). 17 May 2017 (17.05.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/338,111 18 May 2016 (18.05.2016) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 17151843.4 17 January 2017 (17.01.2017) EP KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicants: PIQUR THERAPEUTICS AG [CH/CH]; PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Hochbergerstrasse 60c, 4057 Basel (CH). THE TRUS- SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TEES OF THE UNIVERSITY OF PENNESYLVANIA TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA (84) Designated States (unless otherwise indicated, for every 19104 (US). kind of regional protection available): ARIPO (BW, GH, (72) Inventors: FABBRO, Doriano; Im Lee 54, 4144 Ar- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, leshiem (CH). HEBEISEN, Paul; St. Albanring 184, 4052 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Basel (CH). HILLMANN-WUELLNER, Petra; Dorfs- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = = Title: TREATMENT OF SKIN LESIONS (54) = R 2 1. 1 , 2F . ,. , R ,,), ,4 W F 0 R3_ R4 x';'\"\" , ...,.... . , N > _ = ,..i, (II) ' :::: N N H 2 = — (I) = = A A = = = : The present invention is relates to a compound of formula (I), wherein X 1 , X 2 and X 3 are, independently of each other, N (57) CH; with the proviso that at least two of X 1 X 2 and X are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X 3 1 , X 2 X 3 are N; R 1 and R 2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula or — and - (I); and wherein R 3 and R are independently of each other H, C 4 1 -C 3 alkyl optionally substituted with one or two OH, C 1 -C 2 fluoroalkyl, Ci -C2alkoxy, ClalkoxyCj-C3alkyl, CN, or C(0)0-Ci-C2alkyl; or R 3 and R 4 form together a bivalent residue -R 5 R 6 - selected from C1- Ir -- - iv C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the M bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally GC c:N substituted by 1 to 3 R 7 ; wherein R 7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1- C2fluoroalkyl, --.... Ci-C2alkoxyCj-C3alkyl, C3-C6cycloalkyl; or two R 7 substituents form together a bivalent residue-R R - selected from 8 9 IN p is Il Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2- or -O-CH2CH2-O-; with the proviso that at least one of R 1 and © a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in el the prevention or treatment of a skin lesion in a subject. [Continued on next page] WO 2017/198347 Al MIDEDIMOMOIDEIROIDEMOMMUNDOMOHMEMIDIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338111P | 2016-05-18 | 2016-05-18 | |
| EP17151843 | 2017-01-17 | ||
| PCT/EP2017/025137 WO2017198347A1 (en) | 2016-05-18 | 2017-05-17 | Treatment of skin lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809652PA true SG11201809652PA (en) | 2018-12-28 |
Family
ID=57850922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809652PA SG11201809652PA (en) | 2016-05-18 | 2017-05-17 | Treatment of skin lesions |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3458035A1 (en) |
| AU (1) | AU2017265384B2 (en) |
| CA (1) | CA3022758C (en) |
| SG (1) | SG11201809652PA (en) |
| TW (1) | TWI780049B (en) |
| WO (1) | WO2017198347A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3458067T (en) | 2016-05-18 | 2021-04-07 | Univ Basel | Treatment of neurological disorders |
| WO2019101853A1 (en) | 2017-11-23 | 2019-05-31 | Piqur Therapeutics Ag | Treatment of skin disorders |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
| WO2025181366A1 (en) | 2024-03-01 | 2025-09-04 | Torqur Ag | Topical formulations of dual pi3k/mtor inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2012099968A1 (en) * | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
| BR112013020159A2 (en) * | 2011-02-11 | 2016-11-08 | Dana Farber Cancer Inst Inc | method to inhibit hamartoma tumor cells |
| US9296733B2 (en) * | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CN104245693B (en) * | 2012-12-14 | 2016-08-24 | 上海恒瑞医药有限公司 | Pyrimidine derivatives and their pharmaceutically acceptable salts, their preparation methods and their applications in medicine |
| US20150065431A1 (en) * | 2013-08-27 | 2015-03-05 | Northwestern University | Reducing cutaneous scar formation and treating skin conditions |
| CN103483345B (en) * | 2013-09-25 | 2016-07-06 | 中山大学 | PI3K inhibitors of kinases, the pharmaceutical composition comprising it and application thereof |
| CN104557871B (en) * | 2013-10-28 | 2017-05-03 | 上海汇伦生命科技有限公司 | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof |
| MA40933A (en) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES |
-
2017
- 2017-05-17 SG SG11201809652PA patent/SG11201809652PA/en unknown
- 2017-05-17 CA CA3022758A patent/CA3022758C/en active Active
- 2017-05-17 EP EP17725513.0A patent/EP3458035A1/en active Pending
- 2017-05-17 AU AU2017265384A patent/AU2017265384B2/en active Active
- 2017-05-17 WO PCT/EP2017/025137 patent/WO2017198347A1/en not_active Ceased
- 2017-05-18 TW TW106116464A patent/TWI780049B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017198347A1 (en) | 2017-11-23 |
| CA3022758C (en) | 2024-02-06 |
| TWI780049B (en) | 2022-10-11 |
| AU2017265384B2 (en) | 2023-02-23 |
| WO2017198347A8 (en) | 2025-06-19 |
| AU2017265384A1 (en) | 2018-12-20 |
| EP3458035A1 (en) | 2019-03-27 |
| TW201808943A (en) | 2018-03-16 |
| CA3022758A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer |